한글목차

약제 요약

JNJ-3989(구 ARO-HBV)는 Arrowhead Pharmaceuticals와 Janssen Pharmaceuticals가 공동으로 개발한 3세대 피하투여형 RNAi 치료제 후보물질로, 만성 HBV 감염 환자를 위한 치료제로 개발되었습니다. ARO-HBV는 N-아세틸갈락토사민에 직접 결합하여 간세포로 전달되는 두 개의 siRNA를 포함하고 있으며, ARO-HBV는 공유결합으로 폐쇄된 고리형 DNA(cccDNA)와 숙주에 통합된 바이러스 DNA로부터 형성되는 모든 mRNA를 침묵시킵니다. ARO-HBV는 피하로 투여되기 때문에 흡수와 관련된 약물상호작용(DDI)이 발생하지 않습니다.

JNJ-56136379(JNJ-6379)는 얀센 사이언스가 개발 중인 CAM(Capsid Assembly Modulator)으로, JNJ-66136379(JNJ-6379)는 캡시드 조립을 억제하고 신규 감염시 공유결합으로 폐쇄된 cccDNA를 형성합니다. 폐쇄형 고리형 DNA(cccDNA) 형성을 억제하는 이중 작용기전으로 작용합니다. 이 약은 HBV 핵심 단백질에 결합하여 HBV 수명주기의 초기 및 후기 단계의 과정을 모두 억제합니다. 이 약의 단독요법은 임상 2상에서 바이러스 돌파를 보였으나, 향후 개발이 중단되었습니다.

주요 6 시장(미국·독일·프랑스·이탈리아·스페인·영국)의 B형 만성 간염용 JNJ-73763989에 대해 조사분석했으며, 작용기서, 용법과 용량, 연구개발 활동에 관한 인사이트, 매출의 예측 등을 제공하고 있습니다.

목차

제1장 리포트의 서론

제2장 B형 만성 간염에서 JNJ-73763989의 개요

• 제품의 상세
• 임상 개발
  • 임상 연구
  • 임상시험 정보
  • 안전성과 유효성
• 기타 개발 활동
• 제품 개요

제3장 경쟁 구도(출시 치료법)

제4장 경쟁 구도(후기 신치료법)

제5장 JNJ-73763989 시장 평가

• B형 만성 간염에서 JNJ-73763989의 시장 전망
• 주요 6 시장 분석
  • 주요 6 시장의 B형 만성 간염용 JNJ-73763989의 시장 규모
• 시장 분석 : 국가별
  • 미국의 B형 만성 간염용 JNJ-73763989의 시장 규모
  • 독일의 B형 만성 간염용 JNJ-73763989의 시장 규모
  • 영국의 B형 만성 간염용 JNJ-73763989의 시장 규모

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight 소개

제12장 리포트 구입 옵션

영문목차

"JNJ-73763989 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about JNJ-73763989 for chronic hepatitis B in the six major markets. A detailed picture of the JNJ-73763989 for chronic hepatitis B in the 6MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom for the study period 2019 -2032 is provided in this report along with a detailed description of the JNJ-73763989 for chronic hepatitis B. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the JNJ-73763989 market forecast analysis for chronic hepatitis B in the 6MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in chronic hepatitis B.

Drug Summary:

JNJ-3989, formerly ARO-HBV, a third-generation subcutaneously administered RNAi therapeutic candidate, was developed as a potential treatment for patients with chronic HBV infection in collaboration with Arrowhead Pharmaceuticals and Janssen Pharmaceuticals. ARO-HBV contains two siRNAs directly conjugated to N-acetyl galactosamine for hepatocyte delivery. ARO-HBV silences all mRNAs formed from covalently closed circular DNA (cccDNA) and host-integrated viral DNA. ARO-HBV is administered subcutaneously, so no absorption-related drug-drug interactions (DDI) occur.

JNJ-56136379 (JNJ-6379) is a Capsid Assembly Modulator (CAMs) being developed by Janssen Sciences. It works via a dual mechanism of action, formerly by interfering with capsid assembly and preventing covalently closed circular DNA (cccDNA) formation at de novo infection. It gets attached to the HBV core protein and obstructs both early and late-stage processes in the HBV life cycle. This drug in the monotherapy regimen is discontinued for further development due to the viral breakthrough observed in Phase II.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the JNJ-73763989 description, mechanism of action, dosage and administration, research and development activities in chronic hepatitis B.
• Elaborated details on JNJ-73763989 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the JNJ-73763989 research and development activities in chronic hepatitis B across the United States and Europe.
• The report also covers the patents information with expiry timeline around JNJ-73763989.
• The report contains forecasted sales of JNJ-73763989 for chronic hepatitis B till 2032.
• Comprehensive coverage of the late-stage emerging therapies for chronic hepatitis B.
• The report also features the SWOT analysis with analyst views for JNJ-73763989 in chronic hepatitis B.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

JNJ-73763989 Analytical Perspective by DelveInsight

• In-depth JNJ-73763989 Market Assessment

This report provides a detailed market assessment of JNJ-73763989 for chronic hepatitis B in the six major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom. This segment of the report provides forecasted sales data from 2027 to 2032.

• JNJ-73763989 Clinical Assessment

The report provides the clinical trials information of JNJ-73763989 for chronic hepatitis B covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for chronic hepatitis B is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence JNJ-73763989 dominance.
• Other emerging products for chronic hepatitis B are expected to give tough market competition to JNJ-73763989 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of JNJ-73763989 in chronic hepatitis B.
• Our in-depth analysis of the forecasted sales data of JNJ-73763989 from 2027 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the JNJ-73763989 in chronic hepatitis B.

Key Questions:

• What is the product type, route of administration and mechanism of action of JNJ-73763989?
• What is the clinical trial status of the study related to JNJ-73763989 in chronic hepatitis B and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the JNJ-73763989 development?
• What are the key designations that have been granted to JNJ-73763989 for chronic hepatitis B?
• What is the forecasted market scenario of JNJ-73763989 for chronic hepatitis B?
• What are the forecasted sales of JNJ-73763989 in the six major countries, including the United States, Europe (Germany, France, Italy, Spain), and the United Kingdom?
• What are the other emerging products available and how are these giving competition to JNJ-73763989 for chronic hepatitis B?
• Which are the late-stage emerging therapies under development for the treatment of chronic hepatitis B?

Table of Contents

1. Report Introduction

2. JNJ-73763989 Overview in Chronic hepatitis B

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. JNJ-73763989 Market Assessment

• 5.1. Market Outlook of JNJ-73763989 in Chronic hepatitis B
• 5.2. 6MM Analysis
  • 5.2.1. Market Size of JNJ-73763989 in the 6MM for Chronic hepatitis B
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of JNJ-73763989 in the United States for Chronic hepatitis B
  • 5.3.2. Market Size of JNJ-73763989 in Germany for Chronic hepatitis B
  • 5.3.3. Market Size of JNJ-73763989 in France for Chronic hepatitis B
  • 5.3.4. Market Size of JNJ-73763989 in Italy for Chronic hepatitis B
  • 5.3.5. Market Size of JNJ-73763989 in Spain for Chronic hepatitis B
  • 5.3.6. Market Size of JNJ-73763989 in the United Kingdom for Chronic hepatitis B

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options